Blood Pressure Is Associated with Receiving Intravitreal Anti–Vascular Endothelial Growth Factor Treatment in Patients with Diabetes
- 1 May 2019
- journal article
- research article
- Published by Elsevier in Ophthalmology Retina
- Vol. 3 (5) , 410-416
Abstract
No abstract availableKeywords
Funding Information
- A. Alfred Taubman Medical Research Institute
- Research to Prevent Blindness
This publication has 18 references indexed in Scilit:
- A review of anti-VEGF agents for proliferative diabetic retinopathyEye, 2014
- Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III TrialsOphthalmology, 2013
- Global Prevalence and Major Risk Factors of Diabetic RetinopathyDiabetes Care, 2012
- The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIIOphthalmology, 2008
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Anti-VEGF Agents in the Treatment of Neovascular Age-related Macular Degeneration: Applying Clinical Trial Results to the Treatment of Everyday PatientsAmerican Journal of Ophthalmology, 2007
- The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetesBritish Journal of Clinical Pharmacology, 1999
- Hypertension and diabetic retinopathy---what's the story?British Journal of Ophthalmology, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993